CLINICAL TRIALS PROFILE FOR BONIVA

All Clinical Trials for BONIVA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00148915 ↗	A Study To Assess the Quality and Strength of Bone in Women Participants With Osteoporosis Taking Oral Ibandronate Versus Placebo	Completed	Hoffmann-La Roche	Phase 4	2005-08-01	The purpose of this randomized, double-blind, placebo-controlled study is to estimate the effect of oral ibandronate sodium (Boniva) taken once monthly versus placebo on bone quality and strength at the proximal femur at one year.
NCT00303485 ↗	A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)	Completed	Hoffmann-La Roche	Phase 4	2006-02-01	This study will determine the rapidity of suppression of the bone resorption marker sCTX in post-menopausal women with osteoporosis.Other bone turnover markers will also be evaluated. Patients will be randomised to either monthly Boniva 150mg or placebo, in combination with vitamin D and calcium supplementation. The anticipated time on study treatment is approximately 7 months, and the target sample size is
NCT00377234 ↗	A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.	Completed	Hoffmann-La Roche	Phase 4	2006-05-01	This 2 arm crossover study will evaluate patient reported preference for either once monthly Boniva (150mg p.o.) or once weekly risedronate (35mg p.o.). Patients with post-menopausal osteoporosis will be randomized to receive Boniva for 3 calendar months or risedronate for 12 weeks; they will then cross over to receive the alternative treatment for a further 12 weeks/3 months. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
NCT00545363 ↗	A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP)	Completed	Hoffmann-La Roche	Phase 4	2006-04-01	This 2 arm study will assess the impact of bone marker feedback (BMF), using serum carboxy-terminal collagen crosslinks (CTX) and communication of results at 3 months, on adherence to once monthly ibandronate (150 milligrams [mg] per oral [po]) in women with post-menopausal osteoporosis supported by patient-relationship program (PRP). Participants will be randomized either to receive BMF or no BMF; both groups will be supported by PRP. The anticipated time on study treatment is 3-12 months.
NCT00683163 ↗	PTH & Ibandronate Combination Study (PICS)	Completed	University of California, San Francisco	Phase 2/Phase 3	2008-05-01	This study will test in several innovative ways, several different combinations of PTH and oral monthly ibandronate for the treatment of osteoporosis in postmenopausal women. The intension is to provide other options for treatment than the current standard 2 year course of drug therapy. These options may lead to treatment where the two years of therapy are spread over several years.
NCT00824993 ↗	Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients	Completed	Roche Pharma AG	Phase 3	2008-12-09	The goal of this clinical research study is to see if ibandronate can help to slow the rate of bone loss that may occur in patients who have received a bone marrow transplant for blood cancer. This study plans to address the following hypotheses: 1. The addition of Ibandronate initiated immediately after the transplantation will prevent bone loss in patients undergoing allogenic bone marrow transplantation (BMT) with underlying hematologic malignancies or hematologic disorders. 2. BMT patients who require prolonged steroid and other immunosuppressive treatment for Graft versus Host Diseases(GVHD) have a higher rate of bone loss, which can be prevented or attenuated by Ibandronate. Specific objectives to test these hypotheses are: 1. Primary Objective: 1. To prospectively compare the bone mineral density changes of lumbar spine, femoral neck and total hip between patients randomly assigned to ibandronate and control group over 12 months post bone marrow transplantation at the University of Texas MD Anderson Cancer Center. 2. Secondary Objectives: 1. To measure and compare the accumulated level of steroid used in both treatment and control groups. 2. To collect and compare the level of serum C-terminal telopeptide (CTX) in both treatment and control groups to monitor the bone turnover rate for the duration of the study. 3. To conduct a cost-effectiveness analysis of participating patients for both outcomes on bone mineral density (measured data) and skeletal-related events (modeled data). 4. To record incidence of bone fractures and the graft rate in both treatment and control groups.

Clinical Trial Conditions for BONIVA

Condition Name

Condition Name for BONIVA
Intervention	Trials
Post Menopausal Osteoporosis	4
Postmenopausal Osteoporosis	4
Osteoporosis	3
Healthy	1

Condition MeSH

Condition MeSH for BONIVA
Intervention	Trials
Osteoporosis	12
Osteoporosis, Postmenopausal	8
Bone Diseases, Metabolic	2
Neoplasms	1

Clinical Trial Locations for BONIVA

Trials by Country

Trials by Country for BONIVA
Location	Trials
United States	141
Puerto Rico	2
Latvia	1
Russian Federation	1
Germany	1

Trials by US State

Trials by US State for BONIVA
Location	Trials
California	8
Pennsylvania	7
Georgia	7
New York	6
Florida	6

Clinical Trial Progress for BONIVA

Clinical Trial Phase

Clinical Trial Phase for BONIVA
Clinical Trial Phase	Trials
Phase 4	8
Phase 3	2
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for BONIVA
Clinical Trial Phase	Trials
Completed	13

Clinical Trial Sponsors for BONIVA

Sponsor Name

Sponsor Name for BONIVA
Sponsor	Trials
Hoffmann-La Roche	9
University of California, San Francisco	1
Roche Pharma AG	1

Sponsor Type

Sponsor Type for BONIVA
Sponsor	Trials
Industry	12
Other	2

Boniva (ibandronic acid) Clinical Trials Update and Market Outlook

Last updated: April 28, 2026

What is Boniva and how is it positioned in the osteoporosis market?

Boniva is a bisphosphonate for osteoporosis prevention and treatment. In US commercial practice, the product line includes:

• Oral ibandronate (monthly dosing)
• IV ibandronate (administered by healthcare professionals at scheduled intervals)

Within osteoporosis care, bisphosphonates remain a core option because they are off-patent, widely covered by payers, and supported by long-established clinical evidence. Boniva competes against:

• Other bisphosphonates (generic alendronate, risedronate, ibandronate generics in many markets, zoledronic acid where applicable)
• Denosumab (ongoing use in many formularies)
• Anabolic agents and sequence therapies (e.g., teriparatide, abaloparatide, romosozumab, followed or preceded by antiresorptives)

Boniva’s relative pricing and volume typically track with (1) the availability of low-cost generics for oral bisphosphonates, (2) payer preference for preferred agents, and (3) adherence advantages created by monthly dosing versus weekly oral options.

What is the current clinical-trials signal for Boniva?

Boniva’s modern clinical pipeline activity is limited compared with newer osteoporosis classes. The dominant evidence base consists of prior registration studies and long-term safety data. Current public signals for new, pivotal Boniva trials are sparse and do not match the cadence seen for denosumab or anabolic programs.

From a practical R&D and investment perspective, Boniva’s clinical-trials landscape shows:

• No dominant late-stage, registrational pivot visible in recent public trial cycles that would reset the product’s competitive position
• Ongoing observational and real-world adherence/safety evaluation patterns consistent with mature branded bisphosphonate products
• Incremental comparative work rather than brand-new outcome-defining registrational programs

How does Boniva’s efficacy map to treatment-relevant outcomes?

For osteoporosis, the key clinical endpoints used in practice are fracture reduction (hip and non-vertebral), bone mineral density (BMD) changes, and vertebral fracture outcomes. Bisphosphonates share a class mechanism (inhibition of osteoclast-mediated bone resorption), but their clinical endpoint strength differs by indication and trial populations.

Boniva’s label evidence historically emphasizes:

• Vertebral fracture risk reduction
• BMD improvement
• Hip fracture outcomes depend on study design and population; in practice, other agents may be preferred where hip fracture reduction is the dominant payer requirement

What do recent real-world and adherence patterns imply for market performance?

For mature osteoporosis brands, volume tends to be driven less by “new clinical value” and more by:

• Adherence and persistence (monthly dosing can support better persistence than weekly oral in some populations)
• Formulary placement (especially where payers steer to generics)
• Injection convenience when IV regimens are aligned with local infusion workflows

Boniva’s sales trajectory has historically been sensitive to:

• Generic erosion of oral bisphosphonates
• Biosimilar and biologic competition (denosumab is commonly preferred in patients who fail or cannot tolerate bisphosphonates)
• Institutional preference for agents that fit existing infusion or injection protocols

Market analysis: where Boniva sits versus competitors

Boniva operates in a crowded, pricing-sensitive category. The competitive set in osteoporosis includes:

• Low-cost generics: alendronate and risedronate dominate cost-conscious formularies where generic substitution is permitted.
• Denosumab: often benefits from strong payer acceptance, a simple dosing schedule, and robust patient- and clinician-facing experience.
• Zoledronic acid: where used, it can compete for adherence and persistence through annual dosing.
• Anabolic agents: high cost but important for severe disease and sequence strategies.

Implication for Boniva: branded value is hardest to sustain when:

• oral generics take share, and
• payers shift patients toward denosumab or zoledronic acid based on formulary tiers and preferred dosing patterns.

Market projection: base case, downside, and upside

Because Boniva is mature and operates in a generic-competitive environment, near-term growth is constrained unless a payer or health-system contract re-seats the brand as preferred.

A business-relevant view of projection ranges is as follows (directional, not absolute revenue forecasts):

Base case (most likely): steady to declining, volume-stable in pockets

• Drivers: persistence among adherent cohorts; monthly schedule advantage in patients who stay on oral bisphosphonates.
• Headwinds: ongoing generic substitution pressure; denosumab formulary preference in many lines of therapy.

Downside case: faster share loss to generics and competing antiresorptives

• Drivers: aggressive rebate pressure, broader formulary placement of generic oral bisphosphonates, and substitution to denosumab in higher-risk groups.
• Result: net unit declines and pricing compression.

Upside case: payer-driven preference for monthly IV/optimized contracting

• Drivers: contract wins or pathway adoption for monthly dosing regimens in care settings that value reduced dosing frequency versus weekly oral.
• Result: relative stabilization and potential modest share improvement within selected formularies.

Commercial levers that determine Boniva’s near-term trajectory

For an off-patent branded bisphosphonate, the levers that matter most are not new trial readouts, but commercial execution:

1. Formulary access and rebate positioning

   • Placement in preferred tiers drives script volume.
   • Non-preferred tiers tend to accelerate switching to generics or other classes.

2. Patient selection targeting

   • Patients already stable on the product are more likely to remain adherent.
   • Switches are common when patients newly enter therapy or after adverse events.

3. Administration and care setting workflows

   • For IV regimens, alignment with clinic infusion workflows can reduce friction and support persistence.

4. Clinician switching behavior

   • Adoption is influenced by guideline interpretation, perceived fracture-risk fit, and existing experience with competitor agents.

Regulatory and label considerations

Boniva is an established osteoporosis therapy with a mature regulatory history. The current practical impact for market projections is that the label does not usually create new clinical adoption waves in the way that newly approved therapies do.

Market behavior depends on:

• safety and tolerability in the segment being treated
• payer requirements for prior therapy use and failure criteria
• persistence programs and adherence support programs that reduce discontinuation

Key facts table

Dimension	What matters for Boniva	Market effect
Core indication	Osteoporosis treatment and prevention options via oral monthly and IV regimens	Supports ongoing demand, but does not override generic pressure
Competitive set	Generic bisphosphonates, denosumab, zoledronic acid, sequenced anabolic strategies	Limits branded share growth
Primary value driver	Dosing frequency and real-world persistence	Can stabilize volume in segments
Primary headwinds	Generic substitution and payer steerage	Sustained erosion risk in formularies
Clinical pipeline energy	Mature evidence base; limited late-stage pivots	Lower “new adoption” probability

Key Takeaways

• Boniva is a mature, bisphosphonate-based osteoporosis therapy with limited visible late-stage registrational momentum; the clinical evidence is established and the near-term story is driven by real-world adoption and payer access.
• The brand’s market performance is constrained by generic competition in oral bisphosphonates and by formulary preference shifts toward denosumab and other antiresorptives.
• Near-term market outcomes cluster around steady-to-declining ranges unless a formulary contract or care pathway increases preference for Boniva’s monthly regimens.
• Commercial execution levers that matter most are rebate position, formulary tiering, patient adherence support, and administration workflow fit for IV use.

FAQs

1. Is Boniva still used as a first-line osteoporosis therapy?
   It is used across treatment lines, but first-line adoption is typically influenced by formulary tiering and generic substitution dynamics.

2. What competitor class most pressures Boniva in formulary decisions?
   Denosumab and other antiresorptives with preferred coverage terms often pressure branded bisphosphonates.

3. What drives persistence for Boniva?
   Dosing frequency (monthly oral or scheduled IV) and patient support programs that reduce discontinuation.

4. Do new Boniva trial readouts materially change market outlook?
   No clear registrational-level clinical momentum is apparent; market direction is more responsive to payer access and substitution behavior.

5. What would improve Boniva’s outlook most in the next few years?
   Expanded preferred formulary access through contracting and care pathway adoption that keeps patients on a monthly regimen instead of switching to cheaper oral generics or preferred alternatives.

---

References

[1] FDA. Boniva (ibandronate sodium) prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/ (accessed via FDA label repository for Boniva).